PF-08642534

PF-08642534 is an investigational small molecule agonist of the melanocortin 4 receptor (MC4R) currently in Phase 1 clinical development by Pfizer for the treatment of obesity and chronic weight management. The MC4R is a key component of the leptin-melanocortin pathway in the hypothalamus, where it serves as a critical regulator of energy balance, appetite, and body weight. Activation of MC4R signaling is known to reduce food intake and increase energy expenditure. As an oral small molecule, PF-08642534 is designed to offer a more convenient alternative to existing injectable weight-loss medications, potentially addressing a significant unmet need in the metabolic disease space.